Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00952276 · ClinicalTrials.gov registry record · Phase 2
A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly
A Phase 2 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 2
- Development phase
- 548
- Enrollment target
NCT00952276 is a Phase 2 study that has completed, run by Sanofi. The registered enrollment target is 548 participants.
The verdict
NCT00952276, a Phase 2 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 548 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after a single injection. * To describe the safety of the candidate vaccines after a single injection.
Interventions
- BIOLOGICAL Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant
- BIOLOGICAL Monovalent Subvirion A/H1N1 influenza vaccine
- BIOLOGICAL Normal saline solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 548 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00952276
The ClinicalTrials.gov registry entry for NCT00952276 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 548 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant is the first listed.
NCT00952276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00952276 about?
NCT00952276 is a clinical study titled "A Study of Different Formulations of an Adjuvanted A/H1N1 Pandemic Vaccine in Healthy Adults and the Elderly". The purpose of the study is to evaluate different doses of the Influenza A/H1N1 pandemic vaccine in adults and the elderly. Primary Objectives: * To describe the immunogenicity of the candidate vaccines after a single injection. * To describe the safety of the candidate vaccines after a single inj...
What is the current status of trial NCT00952276?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 548 participants. The study started on 2009-10. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00952276?
The interventions under investigation include: Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant (BIOLOGICAL), Monovalent Subvirion A/H1N1 influenza vaccine (BIOLOGICAL), Normal saline solution (BIOLOGICAL).
Who is sponsoring clinical trial NCT00952276?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.